Healing from within
Conquering lymphatic disorders, restoring the body’s immune system
Latest News
BioBridge Symposium held at 30th World Congress of the International Society of Lymphology (ISL)
Fibralign Corp. and leading physicians presented an update on clinical findings and case studies during the 30th World Congress of the International Society of Lymphology (ISL), which was held 15-19 October 2025 in Antalya, Turkey. As part of this session, Dr. Corrado...
Good Moonwha Hospital completes 100th BioBridge surgical case milestone.
Fibralign Corp. and its South Korean distributor Healing Solutions, LTD announced today that Good Moonwha Hospital completed its 100th BioBridge case in the surgical treatment of lymphedema. Good Moonhwa is the first medical center in Asia and second worldwide to...
Japan BioBridge PMDA Study Completion
Terumo Corporation announced that the first clinical trial conducted in Japan for evaluation the BioBridge® Collagen Matrix in the surgical treatment of lymphedema has reached its endpoint. Terumo is managing and funding clinical studies in Japan which are being used...
About Us
Fibralign is an award-winning, commercial-stage Stanford-spinout that produces novel therapeutic biomedical devices that are designed to address major unmet medical needs.
The company has launched its first product, the BioBridge Collagen Matrix, which has now been used in over 750 surgeries by leading surgeons in 19 countries for the treatment of secondary lymphedema, a global chronic disease that currently has no cure.
BioBridge® Collagen Matrix
-
- BioBridge is a novel thread-like scaffold that has been shown in preclinical and clinical studies to repair damaged lymphatic tissue.
- FDA 510(k) cleared Class II device* for use in soft tissue repair.
- CE mark approved, Class III device for surgical treatment of lymphedema.
- KFDA approval (South Korea).
- Commercially available now in the US, Europe, South Korea and Middle East.
* BioBridge has not been approved by the FDA for treatment of lymphedema.
Nanoweave® Technology
Fibralign is developing a pipeline of compelling novel products which are based on its proprietary Nanoweave® scaffolding platform that can be tailored to address a wide range of high-value applications. Nanoweave technology provides the means to precisely print 3D scaffolding in such a way that mimics human tissue nano structure and directly influence the body’s repair function.
Grants, Awards, Partners and Collaborators
Fibralign has been recognized for its vision and potential to impact lives globally.
We are supported in our mission by world class partners and collaborators.
